Since 2010, Accord Healthcare has registered an average of 12 products a year – at a rate of 1 new launch a month.

Accord Healthcare is currently marketing its generic formulations,  and has several pending registrations,  in the following major therapeutic areas:

  • Oncology and related
  • Cardiovascular
  • Central Nervous System (CNS)
  • Ophthalmics
  • Pain Management
  • Veterinary
  • Musculo-Skeletal
  • Endocrine
  • Anti-Diabetic
  • Dermatological
  • Anti-infective and 
  • Gastro-Intestinal Tract


Accord Healthcare is an accredited BBBEE level 3 contributor.

Accord Healthcare South Africa has been contracted by the state Department of Health to supply state patients with up to 7 000 000 packs of chronic medication in the Cardiovascular and CNS therapeutic categories.

In addition to having access to the rich technology pipeline of the Intas group, we have extensive formulation R & D partnerships and manufacturing collaborations with leading pharmaceutical partners across the globe.

We are a part of the Intas group, which is a diversified multinational pharmaceutical concern with broad capabilities and offerings which include a clinical research organisation operating in the USA, Europe and Asia as well as a pharmacovigilance subsidiary that provides the group with real-time monitoring of safety of patients using our formulations across the globe.

Expansion of trading presence in new markets: Sweden, Denmark, Norway, Belgium, Luxemburg, Austria, Switzerland, Finland, Ireland and Estonia, Latin America and Asia.